These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3562044)

  • 1. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy.
    Guggenbichler JP; Allerberger FJ; Dierich M
    Padiatr Padol; 1986; 21(4):335-42. PubMed ID: 3562044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selection of physiologic bacterial flora by chemotherapeutic agents].
    Allerberger F; Guggenbichler JP; Ausserer B; Fink FM; Dierich MP
    Wien Klin Wochenschr; 1989 Mar; 101(7):233-6. PubMed ID: 2652892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of third-generation cephalosporins on aerobic intestinal flora.
    Guggenbichler JP; Kofler J
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():67-70. PubMed ID: 6094464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cefotaxime and ceftriaxone on the bowel and vaginal flora after single-dose prophylaxis in vaginal hysterectomy.
    Bräutigam HH; Knothe H; Rangoonwala R
    Drugs; 1988; 35 Suppl 2():163-8. PubMed ID: 3135167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone: therapeutic results in various infections and kinetic studies.
    Giamarellou HJ; Tsagarakis J; Petrikkos G; Mavroudis K; Veldekis D; Daikos GK
    Arzneimittelforschung; 1984; 34(3):321-5. PubMed ID: 6329238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of ceftriaxone on aerobic fecal flora in children].
    Borderon JC; Rastegar A; Saliba E; Laugier J; Despert F
    Pathol Biol (Paris); 1990 Sep; 38(7):716-8. PubMed ID: 2235086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study.
    Pilmis B; Jiang O; Mizrahi A; Nguyen Van JC; Lourtet-Hascoët J; Voisin O; Le Lorc'h E; Hubert S; Ménage E; Azria P; Borie MF; Mahé A; Mourad JJ; Trabattoni E; Ganansia O; Zahar JR; Le Monnier A
    Int J Infect Dis; 2021 Mar; 104():617-623. PubMed ID: 33453395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftriaxone therapy of meningitis and serious infections.
    Steele RW
    Am J Med; 1984 Oct; 77(4C):50-3. PubMed ID: 6093519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of ceftriaxone: a review.
    Cleeland R; Squires E
    Am J Med; 1984 Oct; 77(4C):3-11. PubMed ID: 6093515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftriaxone in the treatment of serious infections, particularly after surgery.
    Scully BE; Neu HC
    Am J Surg; 1984 Oct; 148(4A):35-40. PubMed ID: 6091479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin.
    Scully BE; Jules K; Chin NX; Neu HC
    Am J Med; 1987 Apr; 82(4A):336-8. PubMed ID: 3578324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of third-generation cephalosporins on the aerobic intestinal flora.
    Guggenbichler JP; Kofler J; Allerberger F
    Infection; 1985; 13 Suppl 1():S137-9. PubMed ID: 4055044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of long-term preventive use of TMPS on the composition and resistance behavior of aerobic fecal flora].
    Allerberger F; Guggenbichler JP; Ausserer B; Dierich M; Fink FM
    Padiatr Padol; 1987; 22(2):131-7. PubMed ID: 3112699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of ceftriaxone (R013-9904) in the treatment of septicemia caused by gram-negative bacilli].
    Naessens A; Pierard D; Roels P; Lauwers S
    Pathol Biol (Paris); 1983 May; 31(5):362-5. PubMed ID: 6312398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modification of aerobic digestive flora in patients in intensive care during and after treatment with cefmenoxime].
    Poisson DM; Martin P; Bidault C; Gueveler C
    Pathol Biol (Paris); 1989 May; 37(5):350-2. PubMed ID: 2674867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cefotaxime: microbiology, pharmacology, and clinical use.
    Dudley MN; Barriere SL
    Clin Pharm; 1982; 1(2):114-24. PubMed ID: 6309465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The study of drug resistance in aerobic and anaerobic bacterial flora to selected antibacterial drugs].
    Michalska W; Chylak J; Pietkiewicz K
    Med Dosw Mikrobiol; 1996; 48(1-2):61-70. PubMed ID: 8926770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ecological consequences of broad spectrum versus narrow spectrum antibacterial therapy.
    Norrby SR
    Scand J Infect Dis Suppl; 1986; 49():189-95. PubMed ID: 3547623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone and Cefotaxime Have Similar Effects on the Intestinal Microbiota in Human Volunteers Treated by Standard-Dose Regimens.
    Burdet C; Grall N; Linard M; Bridier-Nahmias A; Benhayoun M; Bourabha K; Magnan M; Clermont O; d'Humières C; Tenaillon O; Denamur E; Massias L; Tubiana S; Alavoine L; Andremont A; Mentré F; Duval X;
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.